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Summary: Gaucher disease is the most frequent lysosomal disorder. Its enzyme 
replacement treatment was the new progress of modern biotechnology, successfully 
used in the last years. The evaluation of optimal dose of each patient is important due 
to health and economical reasons. The enzyme replacement is the most expensive 
treatment. It must be held continuously and without interruption. Since 2001, the 
enzyme replacement therapy with Cerezyme*Genzyme was formally introduced in 
Bulgaria, but after some time it was interrupted for 1–2 months. The dose of the 
patients was not  optimal. The aim of our work is to find a mathematical model for 
quantitative evaluation of ERT of Gaucher disease. The model applies a kind of 
software called “Statistika 6” via the input of the individual data of 5-year-old 
children having the Gaucher disease treated with Cerezyme. The output results of the 
model gave possibilities for quantitative evaluation of the individual trends in the 
development of the disease of each child and its correlation. On the basis of this 
results, we might recommend suitable changes in ERT. 
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1. INTRODUCTION 
 
Gaucher disease is the most frequent lysosomal disease. The enzyme  
replacement treatment is a new biotechnology used with success 
around the world  last year. The method was introduced in Bulgaria 
by B. Radeva in 1994. Since 2001 the treatment with 
Cerezyme/Gerezyme is formally registered for use [1-3]. This is one 
of the most expensive biotechnologies and the price of the drug is 
higher. The treatment with ERT must be continuous and without 
interruption. The patient needs optimal doses of Cerezyme. But 
during the treatment in the period 2001-2006, it has been interrupted 
several times for 1–2 months, and the doses have been deleted. 
 
The aim of our work is to find a mathematical model for quantitative 
evaluation of ERT of patients with Gaucher disease. 
 
2. MATERIALS AND METHODS 
 
The patients R.V.T (P.1) and K.P.D (P.2) were diagnosed and treated 
with ERT since 2001–2006 in Clinical Genetics Dept. of the 
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University Children’s Hospital, Sofia. Twice per month, patients 
received infusion with Cerezyme/Genzyme in different doses. RVT, 
4 flacons x200 Uniinfusion per infusion (16 mg⋅kg
-1) and K.P.D.5 
flacons x200 Units per infusion (25 mg⋅kg
-1). Before and during the 
treatment biomarkers were used for monitoring the complete blood 
count: haemoglobin, leucocytes, platelets, the measure of liver and 
spleen, and acid phosphatase and chitotriosidase. 
 
With methods for investigation on time series, the model applies the 
Origin 6 [5] and Statistika 6 [4] software programs with their input 
being the individual data of children with Gaucher disease for 
quantitative evaluation the individual tendency in the development of 
the disease of each child and its correlation. On the basis of these 
results, we were able to recommend suitable changes in ERT. 
 
3. RESULTS 
 
The results showed a positive tendency of decreasing of spleen 
dynamics in the first patient. Spleen = 6879.8 – 3.429*year and 
correlation R
2 = -0.9310 (Fig. 1). 
 
 SPLEEN = 6879,8 - 3,429 * YEAR
Correlation: r = -0,9310
 YEAR
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Fig. 1 Tendency of the spleen dynamics 
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Similar dynamics were exhibited for the liver. Liver = 2921.6 – 
1.457*year and correlation R
2 = -0.8723 (Fig. 2). 
 LIVER = 2921,6 - 1,457 * YEAR
Correlation: r = -0,8723
 YEAR
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Fig. 2 Tendency of the liver dynamics 
 
Haemoglobin showed a positive tendency of increasing of level 
dynamics. Haemoglobin = -1511 + 76000*year and correlation 
R
2=0.893 (Fig. 3). 
 HEMOGLOBIN = -1511, + ,76000 * YEAR
Correlation: r = 0,87930
 YEAR
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Fig. 3 Tendency of the haemoglobin dynamics 
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Platelets of the first patient also showed a positive tendency of dyna-
mics. Platelets = -146E2+7.3143*year and R
2 = 0.82267 (Fig. 4). 
 
 PLATELETS = -146E2 + 7,3143 * YEAR
Correlation: r = 0,82267
 YEAR
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Fig. 4 Tendency of the platelets dynamics 
 
The first patient had a positive tendency of leukocytes dynamics. 
leukocytes = -207.6 + 10571*year and with lower correlation 
R
2 = 0.22903 (Fig. 5). 
 LEUCOCYTES = -207,6 + ,10571 * YEAR
Correlation: r = 0,22903
 YEAR
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Fig. 5 Tendency of the leucocytes dynamics 
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The second patient showed a positive tendency of decreasing the 
spleen dynamics. Spleen = 3512.6 – 1.743*year and correlation 
R
2 = -0.7054 (Fig. 6) 
 
 SPLEEN = 3512,6 - 1,743 * YEAR
Correlation: r = -0,7054
 YEAR
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Fig. 6 Tendency of the spleen dynamics 
 
Liver = 2349 – 1.171*year and correlation R
2 = -0.8303 (Fig. 7). 
 
 LIVER = 2349,8 - 1,171 * YEAR
Correlation: r = -0,8303
 YEAR
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Fig. 7 Tendency of the liver dynamics 
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An increasing tendency of haemoglobin was found in the second 
patient: haemoglobin = 2335+1.1714*year. Correlation R
2=0.94601 
(Fig. 8) and an increasing tendency of platelets dynamics: 
platelets = 8496 + 4.2571*year. Correlation R
2=+0.61198 (Fig. 9). 
 Hemoglobin = -2335, + 1,1714 * YEAR
Correlation: r = 0,94601
 YEAR
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Fig. 8 Tendency of the haemoglobin dynamics 
PLATELETS = -8476, + 4,2571 * YEAR
Correlation: r = 0,61198
 YEAR
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Fig. 9 Tendency of the platelets dynamics 
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The tendency of leukocytes dynamics was flat: 
leukocytes = -305.3 + 0.15429*year. Correlation R
2 = 0.4082 
(Fig. 10) 
 
LEUCOCYTES = -305,3 + ,15429 * YEAR
Correlation: r = 0,40182
 YEAR
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Fig. 10 Tendency of the leucocytes dynamics 
 
4. DISCUSSION 
 
A model was created for the quantitative evaluation of the results of 
ERT with Cerezyme*Genzyme on the basis of the investigation 
dynamics of biomarkers of children with Gaucher disease during a 
treatment with ERT with Cerezyme*Genzyme. Its gave us better and 
easier comparison of the received results. In the first patient there 
were higher correlation between liver, spleen, haemoglobin and 
platelets, than in the second one. But the correlation R
2 of these 
biomarkers were above 0.5, which implies a significant tendency. 
This confirmed again the effect of ERT with recombinant enzyme 
Cerezyme. 
 
It was clear that the second patient needed more enzyme to receive 
better results. It was recommended to increase his doses. The 
dynamics of leukocytes of the first patient were under 0.3 – this is un 
significant tendency because their absolute levels were normal. The 
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second patient showed a moderate tendency of leukocytes dynamics, 
above 0.3 (modarate tendency). 
 
5. CONCLUSION 
 
The developed model for quantitative evaluation, based on the 
method of investigation of time series, gave possibilities for 
longitudinal evaluation of the individual tendency of evolution of the 
disease. On the basis of received data, it was possible to make a 
precise decision about the correction of the individual doses. This 
approach will improve the quality of life of the patients and yield a 
positive economical effect. 
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